FSGS

16 registered clinical trials studyying FSGS — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Evaluate the Safety, Tolerability and PK of SK-09 NCT07267026	Consun Pharmaceutical Group	Phase 1
Not Yet Recruiting	A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis NCT07213960	Apellis Pharmaceuticals, Inc.	Phase 2 / Phase 3
Recruiting	Atacicept in Multiple Glomerular Diseases NCT06983028	Vera Therapeutics, Inc.	Phase 2
Recruiting	Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Trans NCT05508009	Alice Bertaina	Phase 1 / Phase 2
Recruiting	Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Diseas NCT05650619	University of Michigan	—
Unknown	Bortezomib for Treating Glomerular Diseases NCT05383547	Ruijin Hospital	N/A
Recruiting	A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB NCT05183646	Dimerix Bioscience Pty Ltd	Phase 3
Recruiting	NEPTUNE Match Study NCT04571658	University of Michigan	N/A
Recruiting	Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. NCT05505500	University of Michigan	—
Withdrawn	Acthar for Treatment of Post-transplant FSGS NCT02399462	University of North Carolina, Chapel Hill	Phase 4
Completed	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change NCT04009668	University of Michigan	Phase 2
Completed	Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation NCT02683889	University of Colorado, Denver	Phase 3
Completed	A Study of CCX140-B in Subjects With FSGS NCT03536754	Amgen	Phase 2
Terminated	Rituximab to Prevent Recurrence of Proteinuria NCT01164098	George W. Burke	Phase 3
Terminated	The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis NCT01451489	Nanjing University School of Medicine	N/A
Unknown	A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients NCT01468493	Guangdong Provincial People's Hospital	—